Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KIF11 | P52732 | 5/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8403047 | 0.93 | KIF11 (0.55) | TP53MAPTSMN1; SMN2KIF11ABCG2 | |
| SCHEMBL12984720 | 0.91 | TP53 (0.59) | TP53MAPTSMN1; SMN2ABCG2LMNA | |
| SCHEMBL763650 | 0.91 | KIF11 (0.52) | TP53MAPTSMN1; SMN2KIF11ABCG2 | |
| SCHEMBL765213 | 0.90 | ABCG2 (0.54) | TP53MAPTSMN1; SMN2KIF11ABCG2 | |
| SCHEMBL14041751 | 0.89 | KIF11 (0.56) | TP53MAPTSMN1; SMN2KIF11ABCG2 | |
| SCHEMBL14236297 | 0.88 | MAPT (0.51) | TP53MAPTSMN1; SMN2KIF11ABCG2 | |
| SCHEMBL8403050 | 0.86 | ABCG2 (0.57) | TP53MAPTSMN1; SMN2KIF11ABCG2 | |
| SCHEMBL13049882 | 0.86 | LMNA (0.46) | TP53MAPTSMN1; SMN2KIF11ABCG2 | |
| SCHEMBL12982597 | 0.84 | TP53 (0.44) | TP53MAPTSMN1; SMN2KIF11ABCG2 | |
| SCHEMBL764777 | 0.84 | TP53 (0.55) | TP53MAPTSMN1; SMN2KIF11ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871375-B1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PTC THERAPEUTICS INC (US) | 2012-02-29 | — | — | EP | disclosed |